Brought to you by 
Lilly and NextCure pen immuno-oncology deal; Lilly terminates deal
Nov 2018
Executive Summary
Eli Lilly & Co. and NextCure Inc. partnered to discover and develop new immuno-oncology therapies utilizing NextCure’s FIND-IO (Functional, Integrated, NextCure Discovery in Immuno Oncology) platform.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
-
Pharmaceuticals
- Vaccines
Deal Status
- Terminated
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Equity
- Includes Royalty or Profit Split Information
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly and NextCure pen immuno-oncology deal; Lilly terminates deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice